Merck & Company, Inc. vs Zimmer Biomet Holdings, Inc. — Stock Comparison
Q·Score Breakdown
6.7
Neutral
Overall
6.9
Neutral
Quality
Health
Growth
Valuation
Sentiment
MRK
Forward P/E of 11.5× is low relative to sector peers.
ZBH
Earnings growing 34% year-over-year on 9% revenue growth.
⚠ cautious analyst consensus — few Buy ratings.
Analyst Consensus
BUY
Target $129.74 (+15.7%)
27 analysts
HOLD
Target $98.52 (+18.8%)
21 analysts
Fundamentals
MRK
ZBH
31.5×
Trailing P/E
21.5×
11.5×
Forward P/E
9.2×
13.6%
Profit Margin
9.1%
76.6%
Gross Margin
70.2%
—
ROE
6.1%
4.9%
Revenue Growth
9.3%
—
Earnings Growth
34.1%
0.28
Beta
0.61
—
Price / Book
—
$277.0B
Market Cap
$16.0B
$73 – $125
52-Week Range
$80 – $108
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →